#USA #La Jolla #Rhythm AI #STAR Apollo #Mike Dineen

Rhythm AI Appoints Mike Dineen as CEO

Rhythm AI, a cutting-edge MedTech company dedicated to enhancing procedures for atrial fibrillation (AF), has announced the appointment of Mike Dineen as its new Chief Executive Officer. With over 30 years of experience in the MedTech industry, Dineen is a seasoned professional known for his expertise in cardiovascular technologies.

A Critical Appointment at a Pivotal Moment

The announcement comes at a crucial time for Rhythm AI as the company gears up for commercial expansion in the United States. Recently, Rhythm AI received FDA 510(k) clearance for its innovative STAR Apollo™ Mapping System, which is designed to enhance the precision of AF treatments. This system is compatible with the widely utilized CARTO™ 3 Mapping System developed by Johnson & Johnson, as well as Abbott's EnSite™ X EP System. This compatibility helps to establish a patient-specific map of AF, enabling healthcare professionals to tailor their ablation strategies effectively.

Dineen's Impressive Background

Before taking on the role at Rhythm AI, Mike Dineen co-founded Tioga Cardiovascular, developing a transcatheter mitral valve replacement system. His prior leadership role at Kalila Medical saw the company transition from an early-stage prototype to a commercially successful acquisition by Abbott. Throughout his career, Dineen has held several significant positions in prominent MedTech firms, contributing to substantial corporate advancements and innovations.

Dineen has also been instrumental in generating over 60 U.S. patents, showcasing his deep-rooted commitment to innovation in the field. His educational background includes a Bachelor of Science in Biology and a Master of Business Administration from Santa Clara University.

Vision for Rhythm AI

In his new role, Dineen expresses enthusiasm for leading Rhythm AI into its next phase of growth. “STAR Apollo is a clinically meaningful technology, positioned to fundamentally enhance the infrastructure within electrophysiology (EP) labs globally,” he stated. His focus will be to drive the adoption of the STAR Apollo™ Mapping System, generate clinical evidence to increase physician uptake, and build essential partnerships to support the technology's rollout.

Dineen aims to position the STAR Apollo as an indispensable intelligence tool for AF ablation worldwide, emphasizing the importance of collaboration in achieving this ambitious goal.

About Rhythm AI

Founded in 2018 and headquartered in London, UK, Rhythm AI specializes in developing AI-driven software solutions aimed at providing electrophysiologists with enhanced tools for treating atrial fibrillation. The flagship product, STAR Apollo™, is FDA-cleared and leverages live electrogram data to guide precision and targeted ablation strategies. With a commitment to improving outcomes for patients affected by AF, Rhythm AI is well-positioned to transform the standard practices in this medical field.

Visit Rhythm AI's official website to learn more about their innovative solutions and efforts in tackling atrial fibrillation.